More Effective Treatments for Multiple Myeloma Convention Connection: American Society of Hematology Meeting December 2010 Dan Vogl, M.D.
|
|
- Marjory Holmes
- 5 years ago
- Views:
Transcription
1 More Effective Treatments for Multiple Myeloma Convention Connection: American Society of Hematology Meeting December 2010 Dan Vogl, M.D. Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. Please have this discussion you re your own doctor, that s how you ll get care that s most appropriate for you. Andrew Schorr on location in Orlando, Florida, at the meeting of the American Society of Hematology. There are thousands of doctors and researchers from around the world here. Front page news in their daily newspaper is multiple myeloma and all the progress that s been made this year, or the last couple of years, and the prospect of a lot more to come. We got an overview of all this news from Dr. Dan Vogl from Penn Medicine. Dr. Vogl, let s start this way. People are newly diagnosed with myeloma. Maybe they ve never heard of it. They re terrified of the diagnosis. But here we are at this point in time. It sounds like you have more tools than ever before. How would you describe it? So I think it s very clear right now that, for someone newly diagnosed with myeloma, there are a lot of treatment options. Our biggest challenge is deciding which ones to use at which point in the course of the disease to maximize the benefit that we can get from them compared to some of the side effects that we can see from them. So it s very clear that we have a lot of options and a lot of really good treatment options and a good prospect for good responses and long lasting responses that can give people many years of good, quality life. Of course, the question comes up when someone is diagnosed, however that may happen, how do you know what you re dealing with in that patient and when you need to start treatment? So, there are a lot of people who are diagnosed with asymptomatic myeloma, or what we call sometimes a smoldering multiple myeloma. There certainly is a lot of interest in starting treatment early and getting the disease under control before it causes any symptoms. Although, I think at this point, we still don t have any good data that says we should be starting treatment in patients who have no symptoms whatsoever from their multiple myeloma. 1
2 So what we do as part of the evaluation is a careful look for any evidence that the myeloma is truly causing problems. If we find any conclusive evidence that it s causing problems or that the problems are coming up very quickly, that s our indication to start treatment. There are ongoing clinical trials of treatments for people who are truly asymptomatic. But I think right now, outside the context of the clinical trial, we don t have any good reason to start treatment in someone who may continue to have no symptoms from the disease for many years after their initial diagnosis. Now you do a lot of testing when somebody is newly diagnosed. Certainly at Penn you take a very complete look at them. So it s not just one disease, right? It s various subclasses. I think it s very clear, both from what we know about the biology of the disease and from our clinical experience, that we really are dealing with a number of different diseases when we talk about multiple myeloma. There are some tests that we can do that distinguish between some subsets of these diseases, like the cytogenetic testing that we do that tells us, really, whether the biology of the underlying disease is different. Then a lot of what we do is look at people clinically. We see how they re doing and how they respond to therapy and how their disease changes over time, with or without therapy. That tells us a lot about how they re going to do in the future as well. All right, let s talk about these drugs. At this American Society of Hematology meeting over the last few years, it s almost been dizzying the data that s come out on newer medicines. So where are we now with approved medicines and their use, either alone or in combination, giving benefit to patients? So we have, I would say, six or seven approved medicines, three that are probably truly considered new: thalidomide, lenalidomide and bortezomib. Then older medicines, like steroids, dexamethasone and prednisone, cyclophosphamide, melphalan and doxorubicin that also are very effective, especially when used in combinations. Then coming out, there are really many new drugs that have a lot of promise. The closest to clinical use are the newer generation novel agents carfilzomib and pomalidomide. But right behind them are several more that hold a lot of promise for really providing benefit to patients. Okay, let s talk about that for a minute. So the excitement over the last few years has been two groups of medicines, proteasome inhibitors and these so called IMIDs. So you 2
3 mentioned thalidomide and lenalidomide, Revlimid. Then there s bortezomib or Velcade proteasome inhibitor. So tell us, do these work the same or can they work in combination? What s the concept in fighting the cancer cell? So these two classes of medications work very differently in attaching the multiple myeloma cell, as do our older, more traditional chemotherapy agents. Even more than working differently attacking the myeloma cell, they also have very different side effects for the patients. So it s become very clear that it s easy to combine them, in terms of side effects for our patients, and much more effective to combine them. So that you can see better responses when used in combination than when used as a single agent for any of these agents. Okay, in looking ahead, I know there s a, perhaps even approved in the next few months, it s up for consideration, is carfilzomib, which would be a second generation proteasome inhibitor. I believe there s another IMID that could follow lenalidommide, maybe a little further down the road. What would be the advantage of these, yet, newer generation drugs? Carfilzomib is a second generation proteasome inhibitor so very similar in the way that it works to Velcade. It s also very clear that it s an effective medication, like Velcade. Probably the biggest advantage that we re seeing in the clinical trials so far is that, unlike Velcade, which causes, as one of its main side effect, a neuropathy or damage to the nerves, which gives patients numbness, tingling and sometimes pain, carfilzomib doesn t really seem to cause any neuropathy at all. So, while we re still learning where it s going to fit into the overall range of treatments that we have for multiple myeloma, it certainly seems like it s going to be an interesting and useful option for patients who can t tolerate Velcade because of the neuropathy. The new IMID, or immunomodulatory drug, pomalidomide, which is closely related in structure to thalidomide and lenalidomide, appears to be particularly interesting because it seems to be very effective even in patients whose disease has stopped responding to the other two drugs, and especially to lenalidomide, or Revlimid. So with the very encouraging response rate, even in patients who can no longer receive the other medications because they re no long working for their disease. So for someone who s on a journey, hopefully a long journey, with myeloma, it sounds like you re having more lines of therapy where you might start here but, if that is no longer working for you, you have something else. 3
4 Well, you know, we used to think that was had, maybe, two or three lines of therapy to offer any patient with myeloma. But in the clinic now, I think we re routinely seeing that we can treat patients with 8, 10, 12, 15 different lines of therapy over the course of the disease, tailoring each one to the individual situation of the patient in terms of what prior responses they ve had an what prior side effects they ve had from the various treatments they ve received so far. I want to pick up on the second thing you said. Obviously, job one is beat the cancer. But the other is let someone go on with their life, hopefully, with little or no side effects. Side effects from some of the earlier drugs have been not insignificant. So how do you manage that? And what is the importance of communication between the patient and their doctor so that those side effects can be identified and limited? So I think that we have been learning a lot about preventing some of the side effects from our multiple myeloma treatment. Probably one of the biggest areas that we ve learned about is the peripheral neuropathy, or nerve damage, especially from Velcade. What we ve learned is that if you identify that early and make adjustments to the treatment regimen, especially spacing out the doses of Velcade, you can often avoid the worst of the neuropathy symptoms. We found that you can then get people through treatment, eventually get them a full course of treatment with Velcade and a true benefit to their disease. It s really important, therefore, that when patients are going through treatment that when they notice side effects that they let their doctor know immediately so that their doctor has a chance to modify the treatment regimen in ways that can allow it to still be very effective against the disease but minimize the side effects that they re going to get from it. One other area I wanted to ask you about. You re at an academic medical center. You re involved in a lot of clinical trials. So with this landscape changing, newer drugs coming along it looks like, but are all in clinical trials everything has been in a clinical trial it would seem like, at least at your center, that would be part of the discussion. Is there a trial that might be right for me, particularly if I ve gone through other therapies on myeloma? Well, we include clinical trials as part of our treatment options for patients at all stages of their disease. So in our current and upcoming menu of clinical trials, we have options for patients who have asymptomatic myeloma, patients with newly diagnosed disease who have not gotten any therapy, patients who are considering going through a stem cell transplant and patients who have relapsed, or refractory myeloma, who have been through many treatments already before. 4
5 For any of those patients, a clinical trial is an option. They should carefully consider whether going through the process of the clinical trial might be of benefit to them or help provide information for future patients. Because that s really what helps us move our knowledge of myeloma along and move towards eventually finding a cure for this disease. One last thing. Relating to a cure, there s a headline in the newspaper here for doctors who are attending sessions, as you have, in myeloma at this conference about whether you can identify the stem cells where all this comes from and, basically, shut them down or, basically, where the cancer doesn t develop. What s your thought about that, this cure or hope? Well, the idea of finding that myeloma stem cell, or the cell that has the potential to regenerate the entire disease and is thought to be resistant to a lot of the current treatments that we re using, is a great idea that I think we re still working on figuring out. So there are clinical trials going on looking at specific medications that we hope might hit those very resistant, very slow growing cells that eventually cause relapse in our patients. So I think participating in clinical trials is a good idea for that right now. But right now, we don t have a treatment that will truly do that. Okay, so they re describing it in the paper as the Holy Grail. You haven t quite found that yet. No, I don t think we have. But that s it. For someone living with myeloma, newly diagnosed or living with it, it s a much more positive time. I think it really is. I think we have so many treatment options, even just among those approved and available for current use. Then the number of new and encouraging treatments coming down the line is even more hopeful. Thank you very much. You re welcome. 5
6 Truly a very positive and ever-changing landscape of treatments for people diagnosed with multiple myeloma. In Orlando, I m Andrew Schorr. Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. Please have this discussion you re your own doctor, that s how you ll get care that s most appropriate for you. 6
Andrew Schorr: Dr. Stadtmauer, related to multiple myeloma what is the role of transplant today?
The Ongoing Role of Transplant for Multiple Myeloma Convention Connection: American Society of Hematology Meeting December 2010 Edward Stadtmauer, M.D. Please remember the opinions expressed on Patient
More informationTreatment strategies for relapsing and refractory myeloma
Treatment strategies for relapsing and refractory myeloma Dr Guy Pratt #MyelomaInfodays This talk will cover What is relapse and refractory myeloma Treatment options for relapse Treatment options for refractory
More informationHello and welcome to Patient Power. I'm Andrew Schorr. This program is supported through a grant from Onyx Pharmaceuticals.
The Latest Myeloma News From ASH Breaking News December 21, 2010 Sagar Lonial, M.D. Robert Orlowski, M.D. Jack Aiello Please remember the opinions expressed on Patient Power are not necessarily the views
More informationMyeloma treatment algorithm 1999
Outlook for myeloma patients has improved Treatment for relapsed and/or refractory myeloma Dr Guy Pratt Consultant Haematologist, Heart of England NHS Foundation Trust Senior Lecturer, University of Birmingham
More informationThis talk will cover. Treatment for relapsed and/or refractory myeloma. What is relapsed myeloma and refractory myeloma. Treatment options for relapse
This talk will cover Treatment for relapsed and/or refractory myeloma Dr Guy Pratt Consultant Haematologist Heart of England NHS Trust and Senior Lecturer in Haematology University of Birmingham What is
More informationDr Guy Pratt Consultant Haematologist, Heart of England NHS Foundation Trust. Natural course of myeloma. Some definitions. First relapse.
Outlook for myeloma patients has improved Treatment for relapsed and/or refractory myeloma Dr Guy Pratt Consultant Haematologist, Heart of England NHS Foundation Trust Senior Lecturer, University of Birmingham
More informationFour Experts Debate Aggressive Treatment Approaches and the Goal of Complete Response Recorded on April 19, 2014
Patient Power Knowledge. Confidence. Hope. Toward a Cure for Multiple Myeloma: Four Experts Debate Aggressive Treatment Approaches and the Goal of Complete Response Recorded on April 19, 2014 Gareth Morgan,
More informationDo you think you'd be here today if you had not gone to M. D. Anderson?
Advances in Treatment of Multiple Myeloma Webcast November 13, 2007 Michael Wang, M.D. Please remember the opinions expressed on Patient Power are not necessarily the views of M. D. Anderson Cancer Center,
More informationPatient Case and Question
Management of Multiple Myeloma: The Changing Paradigm Relapsed/Refractory Disease Kenneth H. Shain, MD, PhD Assistant Member H. Lee Moffitt Cancer Center Assistant Professor University of South Florida
More informationASH 2014 Coverage: Myeloma Roundtable Discussion Recorded on December 7, 2014
ASH 2014 Coverage: Myeloma Roundtable Discussion Recorded on December 7, 2014 Robert Orlowski, MD, PhD Director of Myeloma and Professor in the Departments of Lymphoma/Myeloma and Experimental Therapeutics,
More informationAndrew Schorr: Is there anything you ve been discussing that you d like to update people about now?
News from ASH: Advances in Bleeding Disorders ASH Conference Coverage December 8, 2008 Craig Kessler, M.D. Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors,
More informationTreatment strategies for relapsing and refractory myeloma
Treatment strategies for relapsing and refractory myeloma Prof Gordon Cook Professor of Haematology and Myeloma Studies University of Leeds & Leeds Cancer Centre #MyelomaInfodays This talk will cover The
More informationMultiple Myeloma Update PMMNG 13 Feb Outline. Alfred Garfall MD Edward Stadtmauer MD
Multiple Update PMMNG 13 Feb 2016 Alfred Garfall MD Edward Stadtmauer MD Outline w Updates on existing/approved drugs for multiple myeloma w Updates on new/upcoming drugs and strategies for multiple myeloma
More informationTreatment options in Myeloma. BritModis myeloma for the elderly care specialist
Treatment options in Myeloma myeloma for the elderly care specialist Dr Richard Soutar, Consultant in Haematology and Transfusion Medicine, Beatson Oncology Centre, Glasgow and The Scottish National Blood
More informationClinical trials for brain tumours
Clinical trials for brain tumours The purpose of clinical trials for brain tumour patients is to gain a better understanding of these tumours and improve diagnosis and treatment. Some trials also seek
More informationMultiple. Powerful thinking advances the cure.
Multiple Myeloma Treatment OVERVIEW Powerful thinking advances the cure www.arztol.com Powerful thinking advances the cure About the Multiple Myeloma Research Foundation The Multiple Myeloma Research Foundation
More informationA Report on the Molly and David Bloom Chair in Multiple Myeloma Research at the Princess Margaret Cancer Centre
A Report on the Molly and David Bloom Chair in Multiple Myeloma Research at the Princess Margaret Cancer Centre April 2013 Table of Contents 1 Introduction 2 Your Support 3 Thank you 10 The Princess Margaret
More informationLiving With Myeloma Treatment and Side Effects Management
Slide 1: Welcome & Introductions OPERATOR: Hello, everyone, and welcome to Living With Myeloma Treatment and Side Effects Management, a free telephone/web education program. It is my pleasure to introduce
More informationReolysin. This Horizons Infosheet contains information on Reolysin, an oncolytic virus being investigated for the treatment of myeloma.
Reolysin This Horizons Infosheet contains information on Reolysin, an oncolytic virus being investigated for the treatment of myeloma. The Horizons Infosheet series provides information relating to novel
More informationBUILDING AN IDEAL WORLD FOR IMPROVING PATIENT OUTCOMES IN ONCOLOGY. Myeloma Canada s experience
BUILDING AN IDEAL WORLD FOR IMPROVING PATIENT OUTCOMES IN ONCOLOGY Myeloma Canada s experience WHO WE ARE Myeloma Canada is a registered non-profit organization created by, and for people living with multiple
More informationMultiple Myeloma Research Consortium Clinical Trial Pipeline
Multiple Myeloma Research Consortium Clinical Trial Pipeline Phase 2 Trial of Combination of Elotuzumab and Lenalidomide +/- Dexamethasone in High-Risk Smoldering Multiple Myeloma NCT02279394 High-Risk
More informationMultiple Myeloma Highlights From the 2015 ASCO Annual Meeting and the 20 th Congress of EHA
Multiple Myeloma Highlights From the 2015 ASCO Annual Meeting and the 20 th Congress of EHA July 13, 2015 Welcome and Introductions Anne Quinn Young, MPH Multiple Myeloma Research Foundation Norwalk, CT
More informationKyprolis. Kyprolis (carfilzomib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.24 Subsection: Antineoplastic Agents Original Policy Date: October 24, 2012 Subject: Kyprolis Page:
More informationMyeloma XII (ACCoRd) Myeloma Infosheet Series. Clinical trials and novel drugs Infoline:
Myeloma XII (ACCoRd) This Infosheet provides information about what the Myeloma XII clinical trial is, why it is taking place and what is involved if patients decide to take part in the trial. This Infosheet
More informationRestrooms Cell phones on silent/vibrate. Refreshments. Patient resource materials
Restrooms Cell phones on silent/vibrate Refreshments Patient resource materials This presentation should not replace discussions with your healthcare provider, but seeks to provide information and resources
More informationThank you, Lizette. I d like to add my welcome to the patients, caregivers and healthcare professionals attending the program today.
WELCOME AND INTRODUCTION Hello everyone. On behalf of The Leukemia & Lymphoma Society (LLS), a warm welcome to all of you. Special thanks to Dr. Larry Anderson for sharing his time and expertise with us
More informationManagement of Multiple Myeloma: The Changing Paradigm
Management of Multiple Myeloma: The Changing Paradigm Relapsed/Refractory Disease Jeffrey A. Zonder, MD Karmanos Cancer Institute Objectives Discuss use of standard myeloma therapies when used as therapy
More informationDecember Northside Multiple Myeloma Support Group Meeting December 8, 2018
December 2018 Northside Multiple Myeloma Support Group Meeting December 8, 2018 The Northside group had their Holiday party on the second Saturday of December. It was well attended and lots of homemade
More informationClinical Policy: Thalidomide (Thalomid) Reference Number: ERX.SPMN.95
Clinical Policy: (Thalomid) Reference Number: ERX.SPMN.95 Effective Date: 07/16 Last Review Date: 06/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationManaging Patients with Multiple Myeloma: What the Specialty Pharmacist Needs to Know
Managing Patients with Multiple Myeloma: What the Specialty Pharmacist Needs to Know Disclaimer: The information within this CME/CE activity is for continuing education purposes only, and is not intended
More informationMyeloma Update on Treatment and Side Effects Management November 7, 2013 Speaker: Asher A. Chanan-Khan, MD
Slide 1 Welcome & Introductions OPERATOR: Hello, everyone, welcome to Myeloma Update on Treatment and, a free telephone-web education program. It is my pleasure to introduce your moderator, Lauren Berger,
More informationNew Treatments Bring Hope to Myeloma Patients
THE LATEST NEWS ON TREATING AND LIVING WITH MYELOMA OUR FOCUS ABOUT treatment options New Treatments Bring Hope to Myeloma Patients DR. SEEMA SINGHAL: MYELOMA EXPERT A dose of optimism is standard treatment
More informationTRANSCRIPT Understanding Next in Class Novel Therapies in Multiple Myeloma: New Classes and Targets
Welcome and Introductions [Slide 1] Thank you so much. Hello everyone and thank you so much for joining us. [Slide 2] This is Joan Levy, and I am the Vice President of Research for the Multiple Myeloma
More informationMyeloma Treatment and Side Effects Management Update
1 Slide 1: Myeloma Treatment and Side Effects Management OPERATOR: Hello, everyone, and welcome to Myeloma Treatment and Side Effects Management Update, a free telephone/web education program. It is my
More informationDaratumumab (Darzalex )
Daratumumab (Darzalex ) This Horizons Infosheet contains information on daratumumab (also known as Darzalex), a drug being investigated for the treatment of myeloma. The Horizons Infosheet series provides
More informationMyeloma Expert Information About Diagnosis and Treatment
Slide 1: Myeloma Expert Information About Diagnosis and Treatment OPERATOR: Hello, everyone, and welcome to Myeloma Expert Information About Diagnosis and Treatment. It is my pleasure to introduce your
More informationBronx, New York Patient-Caregiver Forum November 1, 2017 Page 1 of 9
Bronx, New York Patient-Caregiver Forum November 1, 2017 Page 1 of 9 Speakers: Amit Verma, MD Aditi Shastri, MD Ira Braunschweig, MD Arun Sunny, PA Aditi Shastri, MD: So, I m just going to talk about how
More informationFundraising 101: Structuring and Developing an Effective Fund Raising Operation. Lawrence W. Reed President Mackinac Center for Public Policy
Fundraising 101: Structuring and Developing an Effective Fund Raising Operation Lawrence W. Reed President Mackinac Center for Public Policy In July 2003, Atlas co-sponsored an event with Fundacion DL
More informationHistory of Drug Development in Multiple Myeloma
History of Drug Development in Multiple Myeloma Myeloma Research Roundtable Scottsdale, AZ March 22, 2013 Robert A. Kyle, MD Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida CP1123175-1 Disclosures
More informationClinical Policy: Lenalidomide (Revlimid) Reference Number: CP.CPA.275 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: (Revlimid) Reference Number: CP.CPA.275 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for
More informationA GUIDE TO THIS REFLECTIONS B RESEARCH STUDY IF YOU RE FIGHTING BREAST CANCER, YOU RE NOT ALONE
A GUIDE TO THIS REFLECTIONS B327-02 RESEARCH STUDY IF YOU RE FIGHTING BREAST CANCER, YOU RE NOT ALONE Do you have breast cancer that has spread to outside the breast? Has your tumor tested positive for
More informationPatient Handbook on Stem Cell Therapies
Patient Handbook on Stem Cell Therapies WWW.ISSCR.ORG WWW.CLOSERLOOKATSTEMCELLS.ORG Patient Handbook on Stem Cell Therapies Introduction We have all heard about the extraordinary promise that stem cell
More informationRelapsed/Refractory Multiple Myeloma: Standard of Care Among Emerging Agents
Welcome to Managing Myeloma. My name is Adam Cohen, and I am the Director of Myeloma Immunotherapy and an Assistant Professor in the Hematology/Oncology Division at Abramson Cancer Center of the University
More informationInformation and resources for African Americans living with multiple myeloma and their caregivers
For African Americans living with Multiple Myeloma Information and resources for African Americans living with multiple myeloma and their caregivers Standing in the Gaap: An initiative created to help
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Revlimid) Reference Number: CP.CPA.275 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy
More informationCombined Treatments and Clinical Trials for Better Outcomes in Multiple Myeloma
Combined Treatments and Clinical Trials for Better Outcomes in Multiple Myeloma AZMN Patient Conference March 23, 2013 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael, MD,
More informationTREATMENT OVERVIEW themmrf.org
MULTIPLE MYELOMA TREATMENT OVERVIEW themmrf.org ABOUT THE MULTIPLE MYELOMA RESEARCH FOUNDATION The Multiple Myeloma Research Foundation (MMRF) was established in 1998 by identical twin sisters Kathy Giusti
More informationSmouldering myeloma. Myeloma Infosheet Series. Other related conditions. Infoline:
Smouldering myeloma This Infosheet provides information on what smouldering myeloma is, how it is diagnosed, what the treatment is and will explain the link between smouldering myeloma and active myeloma.
More informationSecret Search Hacks to Find Out What Your Potential Students Really Want.
Secret Search Hacks to Find Out What Your Potential Students Really Want. As a Course Builder, it can be frustrating to hunt down the problem language research you need so much. That s the nature of searches.
More informationMULTIPLE MYELOMA Disease Overview
Speak to a patient support nurse PH: 1.866.603.6628 Email: patientnavigator@themmrf.org MULTIPLE MYELOMA Disease Overview Place stamp here Multiple Myeloma Research Foundation 383 Main Avenue, 5th Floor
More informationMULTIPLE MYELOMA Disease Overview
MULTIPLE MYELOMA Disease Overview ABOUT THE MULTIPLE MYELOMA RESEARCH FOUNDATION After being diagnosed with multiple myeloma in 1998, Kathy Giusti and her sister Karen Andrews, a successful corporate attorney,
More informationYgalo - Targeted Alkylator for the Treatment of Myeloma. Pareto Healthcare Conference: September 7 th, 2017
Ygalo - Targeted Alkylator for the Treatment of Myeloma Pareto Healthcare Conference: September 7 th, 2017 Disclaimer IMPORTANT: You must read the following before continuing. The following applies to
More informationXpertHR Podcast. Original XpertHR podcast: 25 January 2018
XpertHR Podcast Original XpertHR podcast: 25 January 2018 Hello and welcome to this XpertHR podcast with me, Sheila Attwood. Today we ll be looking at leadership development what does it involve and how
More informationmultiple myeloma cancer coaching introduction
multiple myeloma cancer coaching introduction Hi, my name is David Emerson. I want to welcome you to PeopleBeatingCancer.org s Webinar about the Multiple Myeloma Cancer Coaching Program. I am going to
More informationNorthside Multiple Myeloma Support Group Meeting November 3, 2018
November 2018 Northside Multiple Myeloma Support Group Meeting November 3, 2018 Jim M. led the meeting. Jim started the meeting with having everyone introduce himself or herself with a little known fact
More informationMULTIPLE MYELOMA. on New Drugs and Novel Mechanisms of Action in Treating Patients with Multiple
MULTIPLE MYELOMA SANDRA E. KURTIN, RN, MS AOCN, ANP-C Our next session is on New Drugs and Novel Mechanisms of Action in Treating Patients with Multiple Myeloma. Pleased to have here with us today, Ms.
More informationLiving with Multiple Myeloma. multiple myeloma IRELAND INFORMATION & SUPPORT FOR PATIENTS, FAMILIES AND CARERS. Living with MULTIPLE MYELOMA
multiple myeloma IRELAND INFORMATION & SUPPORT FOR PATIENTS, FAMILIES AND CARERS Living with MULTIPLE MYELOMA 1 Multiple Myeloma Ireland www.multiplemyelomaireland.org Multiple Myeloma Ireland is the only
More informationInfopack for relapsed and/or refractory myeloma patients. Infoline:
Infopack for relapsed and/or refractory myeloma patients. 1 1 What is relapsed myeloma? 2 How will I know if I am relapsing? 3 Can the timing of relapse be predicted? 4 Treatment at relapse 5 Refractory
More informationClinical trials patient-education brochure
Released November 2005 Revised January 2008 Revised March 2012 Revised July 17, 2017 Clinical trials patient-education brochure Roslyn Mannon, MD David Rothstein, MD Maria Luisa Alegre, MD, PhD Giorgio
More informationpan-canadian Oncology Drug Review Final Economic Guidance Report Pomalidomide (Pomalyst) for Multiple Myeloma July 31, 2014
pan-canadian Oncology Drug Review Final Economic Guidance Report Pomalidomide (Pomalyst) for Multiple Myeloma July 31, 2014 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationVELCADE (bortezomib) injection
Multiple Myeloma Cancer of the Bone Marrow Understanding VELCADE (bortezomib) injection u-vel_en_2019_r1 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607 USA Telephone: 800.452.CURE (USA & Canada)
More informationThe Cost-Benefit Calculus of CT Angiograms
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/heart-matters/the-cost-benefit-calculus-of-ct-angiograms/4047/
More informationA Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma Paul G. Richardson, M.D., Bart Barlogie, M.D., Ph.D., James Berenson, M.D., Seema Singhal, M.D., Sundar Jagannath, M.D., David Irwin, M.D.,
More informationApplication supported by the Phase 3 MAIA study being reviewed under the FDA Real-Time Oncology Review pilot program
Media Inquiries: Satu Glawe Phone: +49 172 294 6264 Bernadette King Phone: 1-215-778-3027 Investor Relations: Christopher DelOrefice Phone: 1-732-524-2955 Lesley Fishman Phone: 1-732-524-3922 U.S. Medical
More informationThe Myeloma Guide Information for Patients and Caregivers
The Myeloma Guide Information for Patients and Caregivers Manuel, myeloma survivor This publication was supported in part by a grant from Revised 2013 A Message From John Walter President and CEO of The
More informationClinical Trials in Multiple Myeloma in Arizona: Past, Present and Future
Clinical Trials in Multiple Myeloma in Arizona: Past, Present and Future AZMN Roundtable March 2013 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael, MD, MEd, FRCPC, FACP Staff
More informationMyeloma. Your Essential Guide
Myeloma Your Essential Guide Contents 3 Introduction 4 What is myeloma 7 Types of myeloma 9 What causes myeloma? 10 Diagnosis, tests, investigations and staging 14 Treatment of myeloma 19 Initial treatment
More informationManagement of Multiple Myeloma: The Changing Paradigm
Management of Multiple Myeloma: The Changing Paradigm High-Dose Chemotherapy and Stem Cell Transplantation in the Era of Novel Therapies Larry Anderson, MD, PhD Multiple Myeloma and Stem Cell Transplant
More informationHematopoietic Stem Cell Transplant in Myeloma. Gary Simmons, DO
Hematopoietic Stem Cell Transplant in Myeloma Gary Simmons, DO Objectives What is the benefit of ASCT What is Upfront therapy and with novel agent era- does it include ASCT Is response before and after
More informationTo learn more about the MMRF, visit or call Accredited by: 2015 Multiple Myeloma Reseach Foundation
ABOUT THE MULTIPLE MYELOMA RESEARCH FOUNDATION Shortly after being diagnosed with multiple myeloma, Kathy Giusti and her sister Karen Andrews, a successful corporate attorney, founded the MMRF in 1998
More informationMMRF and MMRC. Collaborative Research Model for a Rare Disease. Susan L. Kelley, M.D. MMRF and MMRC 11/23/2009. Collaborative Model
Collaborative Research Model for a Rare Disease Susan L. Kelley, M.D. 1 OVERVIEW Multiple myeloma is an orphan blood cancer with a low 5-year survival rate. African American incidence is twice that of
More informationIANR Performance Management - Manager Conversation Guide
IANR Performance Management - Manager Conversation Guide IANR s performance management conversations allow for open and honest two-way dialogue between employees and managers. During these conversations,
More informationTHE 7 KEYS TO HELP YOU FIND THE Right MARKETING TEAM
DISCOVER THE 7 KEYS TO HELP YOU FIND THE Right MARKETING TEAM by Jimmy Nicholas Founder & CEO of Jimmy Marketing 860.442.9999 www.jimmymarketing.com TABLE OF CONTENTS Welcome Letter from Jimmy Nicholas....................................
More informationTALKING AGILITY: EPISODE 1 PODCAST TRANSCRIPT
TALKING AGILITY: EPISODE 1 PODCAST TRANSCRIPT Welcome to Talking Agility, a podcast from Accenture. Your host is Elitsa Nacheva. Elitsa: This is our very first episode so welcome to everyone who s tuning
More informationPRODUCT IDEATION SAAS ACADEMY
PRODUCT IDEATION SAAS ACADEMY PRODUCT IDEATION Perhaps you re a development agency or a design agency, and you ve been doing work for other people for awhile now. In the process you ve probably found opportunities
More informationOperator Greetings, and welcome to the Living With Myeloma: Managing Side Effects and Quality of Life telephone and Web education program.
WELCOME AND INTRODUCTION Operator Greetings, and welcome to the Living With Myeloma: telephone and Web education program. It is now my pleasure to introduce your moderator,. Thank you, Ms. Figueroa-Rivera.
More informationWorkshop #2: Evolution
The DNA Files: Workshops and Activities The DNA Files workshops are an outreach component of The DNA Files public radio documentary series produced by SoundVision Productions with funding from the National
More informationThalidomide Therapy. Understanding. Improving Lives Finding the Cure. Multiple Myeloma Cancer of the Bone Marrow
Multiple Myeloma Cancer of the Bone Marrow Understanding Thalidomide Therapy u-thal_en_2017_e1 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607 USA Telephone: 800-452-CURE (2873) (USA & Canada)
More informationMultiple Myeloma Training for Physicians 2018
Multiple Myeloma Training for Physicians 2018 Objective and Aim: The National University Cancer Institute, Singapore (NCIS) is the only public cancer centre in Singapore treating both paediatric and adult
More informationVenetoclax (Venclyxto )
Venetoclax (Venclyxto ) This Horizons Infosheet contains information on venetoclax, a drug being investigated for the treatment of myeloma. The Horizons Infosheet series provides information relating to
More informationWendy Poirier, Director of Towers Watsons Canadian Health & Group Benefits Practice talks about the Canadian Rx Coalition
EXCLUSIVE INTERVIEW: Wendy Poirier, Director of Towers Watsons Canadian Health & Group Benefits Practice talks about the Canadian Rx Coalition Today I am pleased to interview Wendy Poirier Director of
More informationCombination Therapies. Inhibitors
Combination Therapies with Immune The Value of Partnerships Checkpoint - Case Study - Inhibitors The Value of Partnerships - Case Study - New data is forecasting that the immune checkpoint inhibitor market
More informationStem Cell Uses and FDA Regulation
Stem cells have been called everything from cure-alls to miracle treatments. But don t believe the hype. Some unscrupulous providers offer stem cell products that are both unapproved and unproven. So beware
More informationAdvances in Stem Cell Transplant for Multiple Myeloma - The Shift to Outpatient Therapy. Gail Sulski, RN, MS, FNP, AOCNP
Advances in Stem Cell Transplant for Multiple Myeloma - The Shift to Outpatient Therapy Gail Sulski, RN, MS, FNP, AOCNP What s New in Myeloma? Shift to Outpatient Transplant New Drugs with higher remission
More informationBest Practices for Trust in the Wireless Emergency Alerts System, page 1
Best Practices for Trust in the Wireless Emergency Alerts Service featuring Robert Ellison and Carol Woody interviewed by Suzanne Miller ---------------------------------------------------------------------------------------------Suzanne
More informationFARYDAK (panobinostat) oral capsule
FARYDAK (panobinostat) oral capsule Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationTRANSCRIPT. Managing Your Myeloma Patient Education Telephone/Web Program WELCOME AND INTRODUCTION. Lizette Figueroa-Rivera, MA
WELCOME AND INTRODUCTION Lizette Figueroa-Rivera, MA Hello everyone. On behalf of The Leukemia & Lymphoma Society (LLS), a warm welcome to all of you. Special thanks to Dr. Craig Cole for sharing his time
More informationHi, I'm Derek Baker, the Executive Editor of the ibm.com home. page, and I'm here today to talk with Dan Pelino, who Is IBM's General Manager for
Hi, I'm Derek Baker, the Executive Editor of the ibm.com home page, and I'm here today to talk with Dan Pelino, who Is IBM's General Manager for the Healthcare and Life Sciences Industries; and also, with
More informationPrincess Margaret Cancer Centre Multiple Myeloma Day Introduction. Anca Prica MD, MSc, FRCPC May 12, 2017
Princess Margaret Cancer Centre Multiple Myeloma Day Introduction Anca Prica MD, MSc, FRCPC May 12, 2017 Who are you? 1) Physician 2) Nurse 3) Pharmacist 4) Trainee 5) Other How many times have you been
More informationA Caregiver s Guide to Helping Myeloma Patients. Webinar 1, February 23, 2017 The New Normal for Caregivers of Patients With Multiple Myeloma
A Caregiver s Guide to Helping Myeloma Patients The New Normal for Caregivers of Patients With Multiple Myeloma Speakers Moderator: Mary DeRome Multiple Myeloma Research Foundation Norwalk, Connecticut
More informationChapter 12 Module 3. AMIS 310 Foundations of Accounting
Chapter 12, Module 3 AMIS 310: Foundations of Accounting Slide 1 CHAPTER 1 MODULE 1 AMIS 310 Foundations of Accounting Professor Marc Smith Hi everyone, welcome back. Let s continue our discussion on cost
More informationGood evening, everyone, and welcome to our accredited. symposium on Risk Stratification in Multiple Myeloma. This symposium is
Risk Stratification in Multiple Myeloma: Putting the Pieces Together Hans Lee, MD, and Tiffany A. Richards, PhD, ANP, AOCNP The University of Texas MD Anderson Cancer Center, Houston, TX FEMALE Good evening,
More informationComments on the ACD Received from the Public Through the NICE Website
Comments on the ACD Received from the Public Through the NICE Website xxxxxxxxxxxxxxxxxxxxx Patient MEDICAL PRACTITIONER ( RETIRED) I RETIRED FROM STRONGLY EVIDENCE BASED GENERAL PRACTICE IN 2004 DUE TO
More informationSmall business guide to hiring and managing apprentices and trainees
Small business guide to hiring and managing apprentices and trainees A short guide for small businesses on how to get the most from your apprentice or trainee When it comes to recruiting and managing a
More informationImmunotherapy in myeloma
Immunotherapy in myeloma Horizons Infosheet Clinical trials and novel drugs This Horizons Infosheet provides information on immunotherapy, a type of treatment being investigated in myeloma. The Horizons
More informationInternational Myeloma Foundation Myeloma Action Month Proclamation Kit
International Myeloma Foundation Myeloma Action Month Proclamation Kit A How-To-Guide for Proclamations 2 Finding Your Champion 3 Sample Cover Letter to Legislator 4 Sample Proclamation.. 5-6 Sample Press
More informationA.K. Because edema should have attenuation of around zero Hounsfield units. D.A.B. Around water? A.K. Around water, yes.
Multiple Myeloma and Dual-Energy CT: Diagnostic Accuracy of Virtual Noncalcium Technique for Detection of Bone Marrow Infiltration of the Spine and Pelvis Radiology 2018; 286:205 213 Aleksander Kosmala,
More informationEVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
perc deliberated upon input from one patient advocacy group and input from registered clinicians regarding the use of daratumumab in patients with multiple myeloma. perc noted that both the patient advocacy
More informationPomalidomide (Imnovid) with bortezomib and dexamethasone for relapsed or refractory multiple myeloma second line and beyond
NIHR Innovation Observatory Evidence Briefing: September 2017 Pomalidomide (Imnovid) with bortezomib and dexamethasone for relapsed or refractory multiple myeloma second line and beyond NIHRIO (HSRIC)
More informationWhat do you do, with an M protein?
What do you do, with an M protein? Cancer Day for Primary Care Emily Rimmer MD FRCPC January 31, 2014 emily.rimmer@cancercare.mb.ca Disclosure of Potential for Conflict of Interest Name of presenter: Emily
More information